AR095435A1 - Formas salinas del (2-(2-(4-fluorofenil)tiazol-4-il)propan-2-il)carbamato de (s)-quinuclidin-3-ilo - Google Patents

Formas salinas del (2-(2-(4-fluorofenil)tiazol-4-il)propan-2-il)carbamato de (s)-quinuclidin-3-ilo

Info

Publication number
AR095435A1
AR095435A1 ARP140100981A ARP140100981A AR095435A1 AR 095435 A1 AR095435 A1 AR 095435A1 AR P140100981 A ARP140100981 A AR P140100981A AR P140100981 A ARP140100981 A AR P140100981A AR 095435 A1 AR095435 A1 AR 095435A1
Authority
AR
Argentina
Prior art keywords
quinuclidin
propan
fluorophenyl
carbamate
tiazol
Prior art date
Application number
ARP140100981A
Other languages
English (en)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50543351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR095435(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AR095435A1 publication Critical patent/AR095435A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicación 1: Una forma cristalina A del malato del (2-(2-(4-fluorofenil)tiazol-4-il)propan-2-il)carbamato de (S)-quinuclidin-3-ilo, en donde dicha difracción de rayos X de polvo contiene el siguiente pico 2-q medido usando la radiación de CuKₐ: 18,095. Reivindicación 7: Una forma cristalina B del malato del (2-(2-(4-fluorofenil)tiazol-4-il)propan-2-il)carbamato de (S)-quinuclidin-3-ilo, en donde dicha difracción de rayos X de polvo contiene el siguiente pico 2-q medido usando la radiación de CuKₐ: 24,355.
ARP140100981A 2013-03-15 2014-03-13 Formas salinas del (2-(2-(4-fluorofenil)tiazol-4-il)propan-2-il)carbamato de (s)-quinuclidin-3-ilo AR095435A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361791706P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR095435A1 true AR095435A1 (es) 2015-10-14

Family

ID=50543351

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100981A AR095435A1 (es) 2013-03-15 2014-03-13 Formas salinas del (2-(2-(4-fluorofenil)tiazol-4-il)propan-2-il)carbamato de (s)-quinuclidin-3-ilo

Country Status (34)

Country Link
US (1) US9518049B2 (es)
EP (1) EP2970250B1 (es)
JP (1) JP6438455B2 (es)
KR (1) KR102302064B1 (es)
CN (1) CN105189490A (es)
AR (1) AR095435A1 (es)
AU (1) AU2014240028B2 (es)
BR (1) BR112015022907B1 (es)
CA (1) CA2906691A1 (es)
CL (1) CL2015002701A1 (es)
DK (1) DK2970250T3 (es)
EA (1) EA037527B1 (es)
ES (1) ES2872326T3 (es)
HK (1) HK1214821A1 (es)
HR (1) HRP20210692T1 (es)
HU (1) HUE054349T2 (es)
IL (1) IL241229B (es)
JO (1) JO3713B1 (es)
LT (1) LT2970250T (es)
MA (1) MA38488A1 (es)
MX (1) MX370178B (es)
MY (1) MY181766A (es)
PH (1) PH12015502021A1 (es)
PL (1) PL2970250T3 (es)
PT (1) PT2970250T (es)
RS (1) RS61852B1 (es)
SA (1) SA515361078B1 (es)
SG (1) SG11201507054YA (es)
SI (1) SI2970250T1 (es)
TN (1) TN2015000427A1 (es)
TW (1) TWI713438B (es)
UY (1) UY35439A (es)
WO (1) WO2014152215A1 (es)
ZA (1) ZA201506602B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105979945A (zh) * 2013-12-11 2016-09-28 建新公司 葡糖神经酰胺合酶抑制剂
US10519157B2 (en) * 2018-02-09 2019-12-31 X-Cutag Therapeutics, Inc. Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof
WO2020163337A1 (en) 2019-02-04 2020-08-13 Genzyme Corporation Treatment of ciliopathies using inhibitors of glucosylceramide synthase (gcs)
MX2022009477A (es) * 2020-02-03 2022-08-22 Genzyme Corp Metodos para el tratamiento de sintomas neurologicos asociados con las enfermedades de almacenamiento lisosomico.
CA3186766A1 (en) 2020-07-24 2022-01-27 Danielle Combessis Pharmaceutical compositions comprising venglustat
MX2023001285A (es) 2020-07-30 2023-02-22 Genzyme Corp Metodos para reducir la concentracion de glicoesfingolipidos en el tejido cerebral y metodos de tratamiento de enfermedades neurodegenerativas que implican los mismos.
WO2022215083A1 (en) * 2021-04-05 2022-10-13 Msn Laboratories Private Limited, R&D Center Solid state forms of (s)-quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl) carbamate or salts and process for its preparation thereof
WO2024116127A1 (en) 2022-12-01 2024-06-06 Genzyme Corporation Venglustat in combination with a strong or moderate inhibitor of cyp3a4

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
IL135578A0 (en) 1997-10-29 2001-05-20 Genzyme Corp Compositions and methods for treating lysosomal storage disease
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
EP1811991B1 (en) 2004-11-10 2018-11-07 Genzyme Corporation Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis
WO2010091104A1 (en) 2009-02-06 2010-08-12 Exelixis, Inc. Glucosylceramide synthase inhibitors
PL3482767T3 (pl) 2009-08-28 2022-02-14 Icahn School Of Medicine At Mount Sinai Enzymatyczna terapia zastępcza ze zwiększaniem dawki do leczenia niedoboru kwaśnej sfingomielinazy
CR20190034A (es) * 2011-03-18 2019-05-20 Genzyme Corp INHIBIDORES DE GLUCOSILCERAMIDA SINTASA (Divisional 2013-0471)

Also Published As

Publication number Publication date
HUE054349T2 (hu) 2021-09-28
EP2970250A1 (en) 2016-01-20
NZ712659A (en) 2020-11-27
MX2015012295A (es) 2016-05-16
CA2906691A1 (en) 2014-09-25
LT2970250T (lt) 2021-05-10
UY35439A (es) 2014-10-31
PH12015502021A1 (en) 2016-01-11
JO3713B1 (ar) 2021-01-31
CN105189490A (zh) 2015-12-23
PT2970250T (pt) 2021-05-07
IL241229B (en) 2019-12-31
BR112015022907A8 (pt) 2019-11-26
HK1214821A1 (zh) 2016-08-05
EA201591706A1 (ru) 2016-02-29
ZA201506602B (en) 2023-04-26
SG11201507054YA (en) 2015-10-29
EA037527B1 (ru) 2021-04-08
MY181766A (en) 2021-01-06
KR102302064B1 (ko) 2021-09-13
KR20150132333A (ko) 2015-11-25
BR112015022907B1 (pt) 2022-07-12
SI2970250T1 (sl) 2021-06-30
TWI713438B (zh) 2020-12-21
TN2015000427A1 (en) 2017-01-03
WO2014152215A1 (en) 2014-09-25
CL2015002701A1 (es) 2016-03-18
DK2970250T3 (da) 2021-07-12
RS61852B1 (sr) 2021-06-30
JP6438455B2 (ja) 2018-12-12
ES2872326T3 (es) 2021-11-02
SA515361078B1 (ar) 2018-06-14
PL2970250T3 (pl) 2021-12-06
TW201502127A (zh) 2015-01-16
AU2014240028A1 (en) 2015-10-15
JP2016513679A (ja) 2016-05-16
AU2014240028B2 (en) 2018-08-02
MA38488A1 (fr) 2017-10-31
IL241229A0 (en) 2015-11-30
US9518049B2 (en) 2016-12-13
EP2970250B1 (en) 2021-04-21
HRP20210692T1 (hr) 2021-06-11
US20160039805A1 (en) 2016-02-11
BR112015022907A2 (pt) 2017-07-18
MX370178B (es) 2019-12-04

Similar Documents

Publication Publication Date Title
AR095435A1 (es) Formas salinas del (2-(2-(4-fluorofenil)tiazol-4-il)propan-2-il)carbamato de (s)-quinuclidin-3-ilo
CY1120173T1 (el) Ενωση πυραζολο-αμιδιου και φαρμακευτικες χρησεις αυτης
JP2016028092A5 (es)
JP2016065085A5 (es)
AR101403A1 (es) (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridin-3-carboxamida, su purificación para su uso como principio activo farmacéutico, un procedimiento para su preparación y su empleo en el tratamiento de enfermedades cardiovasculares
GEP20186933B (en) Substituted dihydroisoquinoline compounds
USD753516S1 (en) Dosimetric helmet
AR095039A1 (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
CL2016001756A1 (es) Preparación farmacéutica que comprende 0,001-0,003 pv de 6-4-pirazol-1-ilbencilpiridin-3-ilsulfonilaminometilpiridin-2-ilaminoacetato de isopropilo o una sal del mismo uso para el tratamiento o prevención de glaucoma o hipertensión ocular.
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
CR20170077A (es) Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
JP2016535100A5 (es)
EA201591397A1 (ru) Хиноксалиноны и дигидрохиноксалиноны как антивирусные средства против респираторно-синцитиального вируса
BR112017013498A2 (pt) composições de inibidor de nitrificação e métodos para a preparação das mesmas
CL2017001467A1 (es) Compuestos de dihidropirimidin - 2 - ona y sus usos médicos
AR103444A1 (es) Forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos
TR201908795T4 (tr) Bi̇r şeki̇llendi̇ri̇lebi̇li̇r kütleni̇n şeki̇llendi̇ri̇lmesi̇ i̇çi̇n ci̇haz
MX2020007268A (es) Regimen de dosificacion de siponimod.
USD751269S1 (en) Ladies open panty
CO2018005491A2 (es) Formulación de combinación de dosis fija, eflornitina y sulindaco
JP2015174929A5 (es)
BR112016026684A2 (pt) Fertilizante à base de enxofre
MX2017003607A (es) Sales de clorhidrato de aluminio que exhiben un pico 1 sec alto.
USD718368S1 (en) Measurement eyeglasses
AR107441A1 (es) Forma cristalina de cobicistat

Legal Events

Date Code Title Description
FB Suspension of granting procedure